Free Trial

Squarepoint Ops LLC Purchases 4,158 Shares of Amedisys, Inc. (NASDAQ:AMED)

Amedisys logo with Medical background

Squarepoint Ops LLC boosted its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,379 shares of the health services provider's stock after purchasing an additional 4,158 shares during the period. Squarepoint Ops LLC owned about 0.57% of Amedisys worth $16,921,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AMED. Blue Trust Inc. boosted its position in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Amedisys in the fourth quarter worth $55,000. Vestcor Inc purchased a new position in shares of Amedisys in the fourth quarter worth $73,000. Venturi Wealth Management LLC raised its stake in shares of Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after purchasing an additional 779 shares during the last quarter. Finally, Covestor Ltd increased its position in Amedisys by 48.8% during the fourth quarter. Covestor Ltd now owns 1,037 shares of the health services provider's stock valued at $94,000 after acquiring an additional 340 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Trading Up 0.6%

AMED stock traded up $0.61 during midday trading on Tuesday, reaching $94.04. 37,820 shares of the company traded hands, compared to its average volume of 340,383. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The business has a 50 day moving average of $93.37 and a 200-day moving average of $91.51. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of 37.32, a P/E/G ratio of 1.78 and a beta of 0.96.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. During the same period in the prior year, the business posted $1.03 earnings per share. The company's quarterly revenue was up 4.1% compared to the same quarter last year. As a group, sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Finally, Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $100.75.

View Our Latest Research Report on Amedisys

Amedisys Company Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines